Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Additional RNAi Patent Applications

NEW YORK, July 29 - Alnylam Pharmaceuticals of Cambridge, Mass., has licensed two groups of patent applications related to RNA interference technology, the company said today.


The first is an exclusive therapeutic license to US Patent Application No. 20030027783, "Inhibiting gene expression with dsRNA," which describes inventions by Magdalena Zernicka-Goetz and colleagues at University of Cambridge that concern "the specific inhibition of gene expression in mammals by bringing the target into contact with double stranded RNA (dsRNA)," according to the application. Alnylam licensed the application, which was published February 6, from Cancer Research Technology of the UK, a licensing arm of Cancer Research UK and other cancer research institutes.


The company also obtained from MIT an exclusive therapeutic license for patent applications for drug-delivery inventions by MIT scientist Robert Langer that can be applied to RNAi therapeutics.


The company did not disclose the financial terms of the licensing agreements.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.